Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

MLA

Prey, S., et al. “Imatinib Mesylate in Scleroderma-Associated Diffuse Skin Fibrosis: A Phase II Multicentre Randomized Double-Blinded Controlled Trial.” The British Journal of Dermatology, vol. 167, no. 5, Nov. 2012, pp. 1138–44. EBSCOhost, https://doi.org/10.1111/j.1365-2133.2012.11186.x.

APA

Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., Kostrzewa, E., Quemeneur, T., Paul, C., Schaeverbeke, T., Seneschal, J., Solanilla, A., Sparsa, A., Bouchet, S., Lepreux, S., … Taïeb, A. (2012). Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. The British Journal of Dermatology, 167(5), 1138–1144. https://doi.org/10.1111/j.1365-2133.2012.11186.x

Chicago

Prey, S, K Ezzedine, A Doussau, A-S Grandoulier, D Barcat, E Chatelus, E Diot, et al. 2012. “Imatinib Mesylate in Scleroderma-Associated Diffuse Skin Fibrosis: A Phase II Multicentre Randomized Double-Blinded Controlled Trial.” The British Journal of Dermatology 167 (5): 1138–44. doi:10.1111/j.1365-2133.2012.11186.x.